Abstract
Molecularly profiling colorectal cancer has opened many potential opportunities for the use of this information in therapeutic decision-making. However, at present, only RAS testing in the metastatic setting has a definitive place in the decision-making paradigm.
Original language | English (US) |
---|---|
Journal | ONCOLOGY (United States) |
Volume | 28 |
Issue number | 2 |
State | Published - Feb 15 2014 |
ASJC Scopus subject areas
- Oncology
- Cancer Research